Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
// Grace O’Malley 1,2 , Madelon Heijltjes 3 , Aileen M. Houston 4 , Sweta Rani 1 , Thomas Ritter 1 , Laurence J. Egan 2 and Aideen E. Ryan 1,2 1 Regenerative Medicine Institute (REMEDI), National Centre for Biomedical Engineering Science (NCBES) NUI, Galway, Ireland 2 Discipline of Pharmacology and Therapeutics, Translational Research Facility, National University of Ireland, Galway, Ireland 3 Leiden University Medical Centre, Leiden, The Netherlands 4 Department of Medicine, University College Cork, Ireland Correspondence to: Aideen E. Ryan, email: // Keywords : mesenchymal stromal cells, tumour microenvironment, colorectal cancer, immunosuppression, immunomodulation Received : February 09, 2016 Accepted : July 09, 2016 Published : August 17, 2016 Abstract The tumour microenvironment (TME) is an important factor in determining the growth and metastasis of colorectal cancer, and can aid tumours by both establishing an immunosuppressive milieu, allowing the tumour avoid immune clearance, and by hampering the efficacy of various therapeutic regimens. The tumour microenvironment is composed of many cell types including tumour, stromal, endothelial and immune cell populations. It is widely accepted that cells present in the TME acquire distinct functional phenotypes that promote tumorigenesis. One such cell type is the mesenchymal stromal cell (MSC). Evidence suggests that MSCs exert effects in the colorectal tumour microenvironment including the promotion of angiogenesis, invasion and metastasis. MSCs immunomodulatory capacity may represent another largely unexplored central feature of MSCs tumour promoting capacity. There is considerable evidence to suggest that MSCs and their secreted factors can influence the innate and adaptive immune responses. MSC-immune cell interactions can skew the proliferation and functional activity of T-cells, dendritic cells, natural killer cells and macrophages, which could favour tumour growth and enable tumours to evade immune cell clearance. A better understanding of the interactions between the malignant cancer cell and stromal components of the TME is key to the development of more specific and efficacious therapies for colorectal cancer. Here, we review and explore MSC- mediated mechanisms of suppressing anti-tumour immune responses in the colon tumour microenvironment. Elucidation of the precise mechanism of immunomodulation exerted by tumour-educated MSCs is critical to inhibiting immunosuppression and immune evasion established by the TME, thus providing an opportunity for targeted and efficacious immunotherapy for colorectal cancer growth and metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“In CRC 5-Fluorouracil (5FU) is one of the first-line therapies for metastatic disease [178].”
BackgroundDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48095-7 · Cited by 2,931 · cited 1×
“Exosomes released from a cell can contain many different components including proteins, lipids, RNA and miRNA [147-150].”
BackgroundMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Macrophage plasticity and polarization in tissue repair and remodelling
Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. (2013) · The Journal of Pathology · doi:10.1002/path.4133 · Cited by 2,384 · cited 1×
“Macrophages can be polarised to an M1 phenotype which secrete reactive oxygen and nitrogen species and inflammatory cytokines, or an M2 phenotype which are involved in the suppression of inflammation and tissue remodelling [99].”
BackgroundRen, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 2×
“, observed reduced tumour growth upon depletion of CAFs (FAP+ cells) from a model of pancreatic ductal adenocarcinoma (PDA), but interestingly only in the presence of CD4 and CD8 cells [52].”
BackgroundTerzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974 · cited 1×
“Could it be that the MSCs, being immunosuppressive, dampen any inflammatory response that so often leads to tumour development in the colon [163, 164], but that excess anti-inflammatory signalling hinders the tumour-immune response? These models could represent the “elimination” phase of the tumour-immune response men…”
BackgroundErez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
Olumi, A., Grossfeld, G., Hayward, S., Carroll, P., Cunha, G., Hein, P., & Tlsty, T. (2000) · Breast Cancer Research · doi:10.1186/bcr138 · Cited by 1,463
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 1×
“, provided some of the earliest evidence to link this MSC-induced immunosuppression to enhanced tumour growth [135].”
BackgroundSuppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · cited 2×
“Kraman [51] Lewis lung carcinoma and pancreatic ductal adenocarcinoma Mouse tumour tissue FAP, α-SMA, Col I (Immunostaining) LLC – depletion of FAP+ cells induced necrosis of tumour cells.”
BackgroundA CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912 · cited 18×
“Fibroblasts are a population of non-vascular, non-epithelial, non-inflammatory cells that form part of and help synthesise connective tissue [13] They are known to play an active role in wound healing, and the activated fibroblasts found in the tumour microenvironment (CAFs) are believed to be of a similar “wound-heal…”
BackgroundResultInfluentialChristianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J.-P., & Belting, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304266110 · Cited by 903 · cited 1×
“Therefore, the mediators of exosome uptake may represent novel targets for therapeutic manipulation [159], although a good deal more investigation is needed in this area.”
BackgroundFlossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Stromal myofibroblasts are drivers of invasive cancer growth
De Wever, O., Demetter, P., Mareel, M., & Bracke, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23925 · Cited by 722
Helbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639 · cited 5×
“In colorectal cancer, NF-κB has been described as the “critical link” between inflammation and cancer, and also found to feature in the wound healing process [58, 62, 63].”
BackgroundInfluentialSpecies Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated Immunosuppression
Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., Zhang, J., Lu, Y., Roberts, A. I., Ji, W., et al. (2009) · Stem Cells · doi:10.1002/stem.118 · Cited by 597
Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts
Direkze, N. C., Hodivala-Dilke, K., Jeffery, R., Hunt, T., Poulsom, R., Oukrif, D., Alison, M. R., & Wright, N. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1708 · Cited by 530
Valenti, R., Huber, V., Filipazzi, P., Pilla, L., Sovena, G., Villa, A., Corbelli, A., Fais, S., Parmiani, G., & Rivoltini, L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1819 · Cited by 493 · cited 1×
“Furthermore, it has been shown that colorectal tumour-derived microvesicles impair monocyte differentiation into dendritic cells and those monocytes that do differentiate in the presence of tumour cell microvesicles exerted a suppressive effect on T-cell activity [156].”
BackgroundExosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo
Zhu, W., Huang, L., Li, Y., Zhang, X., Gu, J., Yan, Y., Xu, X., Wang, M., Qian, H., & Xu, W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.10.002 · Cited by 488 · cited 1×
“There is also evidence to suggest that exosomes released from MCSs can enhance the growth and angiogenesis of tumours in vivo, possibly even to the same extent as MSCs themselves [157] and that these MSC-released exosomes can also induce a state of dormancy in tumour cells that favours their survival until conditions…”
BackgroundMesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417 · cited 9×
“This trial is based upon a number of pre-clinical studies showing potential efficacy in inhibiting tumour growth or metastasis of MSCs engineered to express anti-cancer therapies such as CX3CL-1, TRAIL and IFN-β [169, 172-174].”
BackgroundInfluentialMesenchymal stem cells enhance growth and metastasis of colon cancer
Shinagawa, K., Kitadai, Y., Tanaka, M., Sumida, T., Kodama, M., Higashi, Y., Tanaka, S., Yasui, W., & Chayama, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25440 · Cited by 308
Roodhart, J. M. L., Daenen, L. G. M., Stigter, E. C. A., Prins, H.-J., Gerrits, J., Houthuijzen, J. M., Gerritsen, M. G., Schipper, H. S., Backer, M. J. G., van Amersfoort, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.010 · Cited by 305 · cited 1×
“Recent research has highlighted the ability of MSCs to contribute to resistance to chemotherapeutics in both haematological malignancies and solid tumours [175-177].”
BackgroundChinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266
Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., Kan, B., Du, L., Wang, B., Wei, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.3 · Cited by 173
Targeted Delivery of CX3CL1 to Multiple Lung Tumors by Mesenchymal Stem Cells
Xin, H., Kanehira, M., Mizuguchi, H., Hayakawa, T., Kikuchi, T., Nukiwa, T., & Saijo, Y. (2007) · STEM CELLS · doi:10.1634/stemcells.2006-0461 · Cited by 164 · cited 1×
“More recent research has aimed to harness the tumour-homing property of MSCs to deliver cancerspecific drug or gene therapy to patients, with some positive outcomes being observed [166-170].”
Background
Cited by
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Cell Therapy as Target Therapy against Colon Cancer Stem Cells
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24
Yarahmadi, A., Dorri Giv, M., Hosseininejad, R., Rezaie, A., Mohammadi, N., Afkhami, H., & Farokhi, A. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1472679 · Cited by 21
Metadata
- Authors
- O'Malley, G., Heijltjes, M., Houston, A. M., Rani, S., Ritter, T., Egan, L. J., & Ryan, A. E.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-08-17
- Volume
- 7
- Issue
- 37
- Pages
- 60752-60774
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2515851707
- Cited by
- 71
- References
- 33
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.